Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca, Tufts Join For Neuroscience

by Michael McCoy
July 22, 2013 | A version of this story appeared in Volume 91, Issue 29

AstraZeneca and Tufts University’s medical school will jointly establish a team of postdoctoral researchers at Tufts charged with advancing understanding of disorders of the brain. As part of a three-year agreement, the team will study biological targets of interest in the treatment of diseases including Alzheimer’s and Parkinson’s. AstraZeneca says the new team will complement its neuroscience innovative medicines unit, set up in 2012 to partner with external collaborators. The British firm ended in-house neuroscience research at the time.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.